Legend Capital returned as the RNA drug developer secured $28.8m in a round co-led by Panlin Capital and Trinity Innovation Fund.
China-based drug developer Suzhou Ribo Life Science has secured RMB203m ($28.8m) in a series C1 round featuring Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, China Money Network has reported.
Panlin Capital and Trinity Innovation Fund co-led the round, which also featured SDIC Innovation, Hanyang Capital, Blue Ocean Capital Group, Daxie Yungong Investment, Shenzhen Zhonghui Investment and unnamed additional investors.
Ribo is developing ribonucleic acid (RNA)-focused therapeutics and its pipeline includes prospective treatments in areas such as…
